In This Section

Contact
E-mail
deraedtt [at] email.chop.edu
Location - People View
Room 4028

3501 Civic Center Blvd
Philadelphia, PA 19104
United States

Thomas De Raedt, PhD
Thomas De Raedt
Research Scientist

Dr. De Raedt researches pediatric high grade glioma development and aims to understand the involvement of crucial pathways. He investigates pathway interaction, and explores ways to develop therapies through analyzing human tumors, performing cellular studies, and developing accurate mouse models. This allows Dr. De Raedt and his team to perform novel pre-clinical studies that can lead to clinical trials.

AddtoAny
Share:

Bio

Pediatric high grade glioma (pHGG) is a devastating disease with a median survival of ~12 months. Intriguingly, in pHGG, mutations in the epigenetic machinery often co-occur with RAS pathway mutations. Dr. De Raedt’s goal is to study and understand the RAS pathway itself, and identify and understand how epigenetic mutations cooperate with RAS pathway activation. He also has an interest in developing novel therapeutic approaches, including immunotherapy.

Specifically, Dr. De Readt is investigating functional validation and identification of new epigenetic drivers. In the current era of next generation sequencing, identifying potential new drivers for cancer is no longer a bottleneck. A major challenge, however, remains the rapid functional validation of the vast number of genes that were found mutated or lost. With regards to functional validation, in vivo modeling remains a state-of-the-art discovery tool.

Along with his colleagues, Dr. De Raedt is exploring new therapies for CNS tumors. One of the most promising developments in recent years is the successful application of immunotherapy. Dr. De Raedt anticipates that mouse models he and his colleagues develop will be ideal for testing immunotherapy in central nervous system tumors.

Finally, Dr. De Raedt investigates the activation of RAS transcriptional programs important for transformation. Although RAS signaling cascades have been well studied, a complete picture of which transcription factors downstream of RAS and which direct target genes are important to drive transformation in brain tumors is currently lacking. A profound understanding of the importance of these downstream factors will provide unprecedented mechanistic insight into how the RAS transcriptional program is driven and how it can be exploited for the development of therapies.

Dr. De Raedt’s notable accomplishments and experience include:

  • Expertise in signaling pathways and epigenetics
  • Expertise in mouse modeling
  • Expertise in translational research that has led to multiple clinical trials

Education and Training

BS, Katholieke Universiteit Leuven, Belgium (Bioengineering), 1997

PhD, Katholieke Universiteit Leuven, Belgium (Medical Sciences), 2006

Titles and Academic Titles

Research Scientist

Assistant Professor of Pediatrics

Professional Awards

Scholarship of the Flemish League Against Cancer, 2004

Scholarship of the Belgian American Education Foundation, 2007

Young Investigator Award, Children's Tumor Foundation, 2010

Excellence in Teaching Award, Harvard University, 2011

Publication Highlights

Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K. A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res. 2017 Nov; 77(21):5706-5711. PMID: 28993414
De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, Clapp W, Bradner J, Vidaud M, Upadhyaya M, Legius E, Cichowski K. PRC2 loss amplified Ras-driven transcription and conference sensitivity to BRD4-based therapies.. Nature. 2014 Oct; 514(7521):247-51. PMID: 25119042
Malone CF, Fromm JA, Maertens O, De Raedt T, Ingraham R, Cichowski K. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant Cancers. Cancer Discovery. 2014 Sep; 4(9): 1062-73, Sep 2014. PMID: 24913553
De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, Macleod KF, Cichowski K. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. 20(3):400-13. PMID: 21907929. 2011 Sep; Cancer Cell

Links of Interest